注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Inhibrx Inc是一家专注于各种生物治疗候选药物的临床阶段生物技术公司。该公司的单域抗体(sdAb)平台提供了一个小型、简单、模块化的靶标结合域,可以组合起来以满足每个生物靶标的需求。其产品线包括:INBRX-101是一种由两个人类AAT组成的重组α-1抗胰蛋白酶(AAT)蛋白,并由分子共价连接到人类免疫球蛋白G4的可结晶片段(Fc)区域;INBRX-109是一种精确设计的四价sdAb为基础的靶向死亡受体5(DR5)治疗候选药物,其sdAb平台设计用于驱动癌症选择性程序性细胞死亡并最大限度地提高效力,同时最大限度地减少肝细胞凋亡引起的靶向肝毒性;INBRX-105是一种精确设计的基于多特异性sdAb的治疗候选药物,旨在在PD-L1存在的情况下选择性地激动4-1BB。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Guy S. Salvesen | - | - | Scientific Advisor |
Victor Nizet | - | - | Member of Advisory Board |
Douglas Gorman Forsyth | 54 | 2018 | Independent Director |
Kimberly J. Manhard | 63 | 2020 | Independent Director |
Kristiina Vuori | 55 | 2021 | Independent Director |
Mark Brantly | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Robert A. Sandhaus | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Rand P. Mulford | 79 | - | Member of Advisory Board |
Stephen B. Howell | 78 | - | Member of Advisory Board |
Mark Paul Lappe | 56 | 2010 | Founder, Chairman, President & CEO |
Igor Barjaktarevic | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Kenneth R. Chapman | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
John Faiz Kayyem | 59 | 2018 | Independent Director |
James K. Stoller | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
Noel Gerry McElvaney | - | 2022 | Member of INBRX-101 Scientific Advisory Board |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核